Type 2 Diabetes Mellitus

Blaha, Michael J.; Khorsandi, Michael

doi:10.1016/j.jacc.2023.08.033

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To significantly decrease cardiovascular risk in individuals with type 2 diabetes as ASCVD, a coordinated approach is crucial, incorporating lifestyle adjustments, nutritional counseling, and outcomes‐based medications. 53 Meta‐analysis of six randomized controlled trials, demonstrated that sodium‐glucose cotransporter‐2 (SGLT2) inhibitors substantially reduce MACE, particularly decreasing the risk of HF hospitalization and progression of kidney disease in type 2 diabetes patients. 54 Similarly, an analysis of eight trials revealed that glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) not only lower MACE but also contribute significantly to reducing all‐cause mortality, HF hospitalizations, and the progression of kidney disease.…”

Section: Introductionmentioning

confidence: 99%

The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease

Khorsandi,

Blumenthal,

Blaha

et al. 2024

Clinical Cardiology

Self Cite

View full text Add to dashboard Cite

BackgroundThe 2023 Multisociety Guideline for the Management of Chronic Coronary Disease (CCD) updates recommendations for CCD, formerly known as “stable ischemic heart disease.” This condition encompasses a spectrum of coronary vascular pathologies from subclinical to clinical ischemic heart disease.HypothesisThe new “ABC” mnemonic offers clinicians a streamlined framework for applying Class One Recommendations (COR1) and integrating recent updates into CCD management.MethodsA critical analysis of the 2023 CCD guidelines was conducted, with this review highlighting key elements.ResultsThe review outlines crucial changes, including novel recommendations supported by current clinical evidence. The focus is on these developments, clarifying their importance for day‐to‐day clinical practice.ConclusionsThe review encourages a synergistic approach between primary healthcare providers and cardiologists to develop comprehensive strategies for lifestyle modification and medication therapy in CCD care. Furthermore, it suggests that utilizing comprehensive risk assessment tools can refine medical decision‐making, ultimately enhancing patient care and clinical outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease

Khorsandi,

Blumenthal,

Blaha

et al. 2024

Clinical Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

Impact of Diabetes Mellitus on Atrial Fibrillation Recurrence and Major Adverse Cardiac and Cerebrovascular Events following Catheter Ablation

Lin,

Wang,

Rong

et al. 2024

International Journal of Clinical Practice

View full text Add to dashboard Cite

Introduction. Further evidence is required to understand the impact of preexisting and newly diagnosed diabetes mellitus (DM) on atrial fibrillation (AF) recurrence and major adverse cardiac and cerebrovascular events (MACCEs) following catheter ablation. Materials and Methods. Data from 1,685 patients (1,406 without DM vs. 279 with DM) who underwent AF catheter ablation between 2015 and 2019 were analyzed. These participants were prospectively monitored for incidents of AF recurrence and MACCE over an average period of 58.1 months. Results. A higher incidence of AF recurrence (24.6% vs. 34.4%) and a greater frequency of MACCE (6.5% vs. 9.3%) were observed among DM patients. Kaplan–Meier curves indicated that DM significantly increased the rates of AF recurrence, with a hazard ratio (HR) of 1.506 and a 95% confidence interval (CI) of 1.165–1.948 (p = 0.0003). This association persisted in the propensity‐matched cohort. DM was independently predictive of AF recurrence after adjusting for potential risks using Cox regression analysis. Notably, new‐onset DM was also found to be an independent predictor of AF recurrence. Similarly, DM was an independent risk of MACCE (HR [95% CI], 2.273 [1.120–4.615], p = 0.023). Conclusions. Both existing DM and newly diagnosed DM were identified as independent risk factors for AF recurrence following ablation; they also significantly impacted MACCE outcomes. This study underscores the urgent need for careful management of DM among individuals undergoing AF ablation in order to reduce the likelihood of arrhythmic relapse. This analysis utilized data from a prospective observational study registered in the Chinese Clinical Trial Registry on July 20, 2014 (ChiCTR-OCH-14004674).

show abstract

Type 2 Diabetes Mellitus

Cited by 2 publications

References 7 publications

The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease

The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease

Impact of Diabetes Mellitus on Atrial Fibrillation Recurrence and Major Adverse Cardiac and Cerebrovascular Events following Catheter Ablation

Contact Info

Product

Resources

About